Wall Street analysts expect Anavex Life Sciences Corp. (NASDAQ:AVXL) to report earnings of ($0.10) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Anavex Life Sciences’ earnings. Anavex Life Sciences reported earnings of ($0.09) per share in the same quarter last year, which indicates a negative year over year growth rate of 11.1%. The business is expected to report its next quarterly earnings results on Wednesday, May 9th.
On average, analysts expect that Anavex Life Sciences will report full year earnings of ($0.41) per share for the current fiscal year, with EPS estimates ranging from ($0.42) to ($0.40). For the next fiscal year, analysts forecast that the company will report earnings of ($0.48) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Anavex Life Sciences.
Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Wednesday, February 7th. The biotechnology company reported ($0.09) EPS for the quarter.
A number of equities research analysts have recently issued reports on AVXL shares. Maxim Group set a $5.00 price target on shares of Anavex Life Sciences and gave the company a “buy” rating in a research note on Thursday, February 8th. Noble Financial reissued a “buy” rating on shares of Anavex Life Sciences in a research note on Wednesday, February 21st. Roth Capital started coverage on shares of Anavex Life Sciences in a research note on Thursday, March 8th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Zacks Investment Research raised shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Thursday, March 22nd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $7.19.
Several institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC raised its stake in shares of Anavex Life Sciences by 95.2% in the 4th quarter. Millennium Management LLC now owns 44,895 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 21,895 shares during the period. Deutsche Bank AG raised its stake in shares of Anavex Life Sciences by 150.9% in the 4th quarter. Deutsche Bank AG now owns 82,967 shares of the biotechnology company’s stock valued at $266,000 after acquiring an additional 49,904 shares during the period. Bank of New York Mellon Corp increased its stake in Anavex Life Sciences by 60.3% during the 4th quarter. Bank of New York Mellon Corp now owns 177,938 shares of the biotechnology company’s stock worth $573,000 after buying an additional 66,931 shares during the period. Wells Fargo & Company MN increased its stake in Anavex Life Sciences by 40.8% during the 3rd quarter. Wells Fargo & Company MN now owns 56,873 shares of the biotechnology company’s stock worth $236,000 after buying an additional 16,488 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Anavex Life Sciences by 37.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,876 shares of the biotechnology company’s stock worth $169,000 after buying an additional 8,728 shares during the period. 22.75% of the stock is currently owned by institutional investors and hedge funds.
AVXL stock traded down $0.11 during trading on Tuesday, reaching $2.12. 1,023,289 shares of the stock were exchanged, compared to its average volume of 298,748. Anavex Life Sciences has a 1 year low of $1.85 and a 1 year high of $6.27. The company has a market capitalization of $95.83, a PE ratio of -6.36 and a beta of 0.87.
TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/17/anavex-life-sciences-corp-avxl-expected-to-post-earnings-of-0-10-per-share.html.
About Anavex Life Sciences
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Get a free copy of the Zacks research report on Anavex Life Sciences (AVXL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.